옵션 체인은 다양한 행사가격과 만기일에 대한 Vaccinex의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Vaccinex에 대한 시장 심리를 평가합니다..

Vaccinex (NASDAQ:VCNX) 주식, 옵션 체인

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

News

Guidance

Pfizer Provides Its Full-year 2025 Guidance And Reaffirms Its Full-year 2024 Guidance

Piper Sandler analyst Patrick Moley initiates coverage on MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Overweight rating and announces Price Target of $34.

Price Target

Initiation

Analyst Ratings

MARA

Piper Sandler Initiates Coverage On MARA Holdings with Overweight Rating, Announces Price Target of $34

Compass Point analyst Casey Alexander upgrades Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) from Sell to Neutral and announces $8.25 price target.

Upgrades

HRZN

Compass Point Upgrades Horizon Tech Finance to Neutral, Announces $8.25 Price Target

Oppenheimer analyst Steve Lichtman initiates coverage on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform rating and announces Price Target of $275.

Oppenheimer Initiates Coverage On Penumbra with Outperform Rating, Announces Price Target of $275

On Monday, December 16th, U.S. markets closed mixed, with the Nasdaq reaching a record high and the S&amp;P 500 rising as investors anticipated the Federal Reserve&#8217;s policy decision and a likely rate cut. Gains in the consumer sector offset weaker manufacturing data. Investor sentiment remained upbeat, driven by hopes for easing rates and economic resilience.
On the economic front, the NY Empire State Manufacturing Index dropped sharply to 0.20 in December from 31.2 the previous month, missing expectations. Meanwhile, the S&amp;P Global services PMI rose to 58.5 in December, while the manufacturing PMI fell to 48.3 from 49.7 in November.
Most S&amp;P 500 sectors closed lower, led by materials, energy, and healthcare, while consumer discretionary and communication services outperformed, ending higher.
The Dow Jones Industrial Average was down 0.25% and closed at 43,717.48, the S&amp;P 500 closed higher by 0.38% to 6,074.08, while the Nasdaq Composite rose 1.24% to finish at 20,173.89.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 declined 0.13% and ended the session at 39,410.00, led by losses in the Shipbuilding, Warehousing, and Precision Instruments sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.78% and ended the day at 8,314.00, led by gains in the Industrials, IT, and A-REITs sectors.</li>
<li>India&#8217;s Nifty 50 slid 1.41% to 24,320.30, and Nifty 500 was down 1.19%, closing at 23,075.15.</li>
<li>China&#8217;s Shanghai Composite fell 0.73% to close at 3,361.49, while the Shenzhen CSI 300 gained 0.26%, finishing the day at 3,922.03.</li>
<li>Hong Kong&#8217;s Hang Seng was down 0.48% and closed the session at 19,700.48.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was up 0.32%.</li>
<li>Germany&#8217;s DAX gained 0.18%.</li>
<li>France&#8217;s CAC rose 0.28%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.75%.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 1.44% at $69.69/bbl, and Brent was down 0.72% at $73.39/bbl.</li>
<li>Oil prices fell due to weak Chinese economic data and caution ahead of the Fed&#8217;s interest rate decision.</li>
<li>Natural Gas rose 0.65% to $3.235.</li>
<li>Gold was trading lower by 0.53% at $2,655.99, Silver was down 1.16% to $30.700, and Copper fell 1.14% to $4.1435.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were down 0.35%, S&amp;P 500 futures fell 0.25% and Nasdaq 100 futures slid 0.04%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index was up 0.17% to 107.03, USD/JPY was down 0.22% at 153.81, and USD/AUD rose 0.47% to 1.5770.</li>
<li>The U.S. dollar remained strong ahead of the Federal Reserve&#8217;s expected rate cut, supported by robust economic data and higher yields.</li>
</ul>
Image via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mostly Lower, Europe Markets Up As Dollar Strengthens Ahead Of Fed Rate Decision - Global Markets Today While US Slept

Oppenheimer analyst Steve Lichtman initiates coverage on Inari Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) with a Outperform rating and announces Price Target of $75.

NARI

Oppenheimer Initiates Coverage On Inari Medical with Outperform Rating, Announces Price Target of $75

Correction: Telsey Advisory Group analyst Joe Feldman upgrades Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) from Market Perform to Outperform and raises the price target from $21 to $26. (Rating changed)

Correction: Telsey Advisory Group Upgrades Albertsons Companies to Outperform, Raises Price Target to $26 (Rating changed)

Telsey Advisory Group analyst Joe Feldman maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and raises the price target from $21 to $26.

Telsey Advisory Group Maintains Outperform on Albertsons Companies, Raises Price Target to $26

Mizuho analyst Vijay Rakesh upgrades Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Neutral to Outperform and raises the price target from $230 to $515.

TSLA

Mizuho Upgrades Tesla to Outperform, Raises Price Target to $515

This approximate gross Bitcoin mining revenue figure is based upon a Bitcoin price of $106,000.

GPUS

Hyperscale Data Says Subsidiary ACS Mined 20 Bitcoin During November 2024 Resulting In Annualized Run Rate Of $26M In Gross Bitcoin Mining Revenue

Elon Musk has expressed admiration for Alphabet Inc.&#8217;s (NASDAQ: GOOG0 (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) <a href="https://www.benzinga.com/24/12/42514620/googles-veo-2-and-imagen-3-set-new-standards-for-ai-creativity">new AI video tool</a>, Veo 2, as it enters the competitive landscape against OpenAI&#8217;s Sora.
What Happened: On Monday, Google introduced Veo 2, a cutting-edge AI video tool, alongside its enhanced Imagen 3 image models.
Veo 2 boasts features like up to 4K resolution, extended video lengths, shallow depth of field, and specific lens types.&nbsp;
The company's CEO Sundar Pichai showcased videos generated by Veo 2 on X, formerly Twitter, demonstrating its potential.&nbsp;
See Also: <a href="https://www.benzinga.com/24/12/42499106/microsofts-iphone-file-sharing-apples-watch-ultra-1-2-billion-lawsuit-and-more-this-week-in-appleverse?itm_source=parsely-api">Microsoft&#8217;s iPhone File Sharing, Apple&#8217;s Watch Ultra, $1.2 Billion Lawsuit And More: This Week In Appleverse</a>
Replying to him, xAI founder Musk said, &#8220;Looks impressive,&#8221; referring to the videos generated by the model.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Looks impressive
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1868814824626700318?ref_src=twsrc%5Etfw">December 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk also shared a post by prominent investor Jason Calacanis, who stated that both Google's Gemini and xAI's Grok models have now "reached parity, and in some cases are much better," than OpenAI's ChatGPT.
Calacanis noted that his use of all three models—Google's Gemini, Grok, and ChatGPT—had shifted dramatically over the past month, with Google's tools now handling more than 50% of his queries, a sharp increase from the previous 90% reliance on ChatGPT.
Calacanis said, "It's now a data and UI game, and I think Reddit, X/Twitter, and Google's dataset will trounce OpenAI's lack of data."
His statement underscores the growing belief that Google's data advantages and advanced AI tools could soon outpace OpenAI in several key areas.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Google/Gemini and Grok have reached parity, and in some cases are much better, than ChatGPT I use all three, every day, at least 50-100x … ChatGPT went from 90% of my queries last month to &lt; 50% It's now a data and UI game, and I think Reddit, X/twitter and google's… <a href="https://t.co/4tOEBz1ffB">https://t.co/4tOEBz1ffB</a>
&mdash; @jason (@Jason) <a href="https://twitter.com/Jason/status/1868710433139376358?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Previously, Marc Andreessen commended <a href="https://www.benzinga.com/tech/24/12/42501018/marc-andreessen-praises-openais-sora-video-model-we-may-have-basically-just-solved-the-fundamental-challenge-of-robotics">OpenAI's Sora video model</a> for tackling a major challenge in robotics by enabling the creation of realistic video.
He highlighted the model's capability to produce 3D-realistic video from text inputs, effectively simulating intricate elements such as lighting and reflections that are crucial for real-world navigation.
However, apart from OpenAI's Sora, Google's latest model competes with several other companies.
Earlier this year, Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) launched its AI-driven video tool aimed at advertisers, entering the market alongside Adobe's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) Firefly <a href="https://www.benzinga.com/markets/equities/24/09/40819405/adobe-shakes-up-video-editing-with-ai-powered-creation-tools-whats-on-the-cards">Video Model</a>.
In October 2024, Meta Platforms Inc. (META) also unveiled Movie Gen, a new tool <a href="https://www.benzinga.com/top-stories/24/10/41188250/metas-movie-gen-brings-ai-powered-video-audio-creation-to-all">designed to create videos</a>, images, and audio from text prompts.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42495758/elon-musk-finds-an-unlikely-ally-in-mark-zuckerbergs-meta-in-his-fight-against-sam-altmans-openai?itm_source=parsely-api">Elon Musk Finds An Unlikely Ally In Mark Zuckerberg&#8217;s Meta In His Fight Against Sam Altman&#8217;s OpenAI</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Tech

ADBE

AMZN

GOOGL

Elon Musk Reacts After Sundar Pichai Shares Veo 2 As Google Looks To Challenge OpenAI's Sora In AI Video Race: 'Looks Impressive'

SkyAlyne Partners With CGI To Deliver IT Solutions For Canada's 25-Year Future Aircrew Training Program

Through this existing collaboration, Evonik's proprietary biodegradable long-acting PLGA (RESOMER) microparticle formulation was used for SIL-204, Silexion's next-generation siRNA candidate. This innovative formulation has demonstrated high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. By leveraging Evonik's formulation expertise, Silexion aims to deliver sustained-release RNAi therapy, allowing for more effective targeting of KRAS mutations—one of the most challenging genetic drivers in oncology.

Biotech

Health Care

General

SLXN

Silexion Therapeutics Revealed Its Ongoing Collaboration With Evonik For The Development Of An Advanced siRNA Formulation Aimed At Enhancing Cancer Treatment Efficacy

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) ("Affimed," or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced updated clinical data from the ongoing AFM24-102 trial of AFM24/atezolizumab combination therapy in heavily pretreated NSCLC patients. Results continue to demonstrate meaningful clinical activity in both NSCLC EGFRwt and EGFRmut patients with good tolerability. In addition, the Company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24 showing higher AFM24 exposure is associated with significantly better response rates, improved PFS and overall survival (OS). Based on these data, the future development program for AFM24 will use a dose of 720 mg weekly, a dose that has already been successfully tested in the phase 1 study of AFM24 showing a manageable safety profile.

AFMD

Affimed Reports Results for Cancer Therapy in NSCLC Patients

Management

Brazil Potash Appoints Mayo Schmidt As Executive Chairman Of Its Board, Effective January 6, 2025

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) with a Buy and lowers the price target from $20 to $13.

Reiteration

FHTX

HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Lowers Price Target to $13

Jefferies analyst Omar Nokta maintains Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) with a Buy and lowers the price target from $26 to $20.

Jefferies Maintains Buy on Frontline, Lowers Price Target to $20

Morgan Stanley analyst Angel Castillo upgrades WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from Equal-Weight to Overweight and raises the price target from $40 to $50.

Morgan Stanley Upgrades WillScot Holdings to Overweight, Raises Price Target to $50

Jefferies analyst Omar Nokta maintains Hafnia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NYSE">HAFN</a>) with a Buy and lowers the price target from $8 to $6.5.

HAFN

Jefferies Maintains Buy on Hafnia, Lowers Price Target to $6.5

Merrill Lynch & Strategic Return Notes for Select 10 Index

Reported Earlier, Maison Solutions Reiterates FY25 Guidance: Revenues $120M - $125M, Net Income Positive

The latest announcement is out from Vaccinex (VCNX). Vaccinex, Inc. has announced new insights from its SIGNAL-AD Phase 1b/2 trial assessing the pe...

Vaccinex Provides Update on Alzheimer's Treatment Trial

Vaccinex says Alzheimer's candidate buoyed by additional early-stage data

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) just reported results for the second quarter of 2024.<ul><li>Vaccinex reported earnings per share of -$3.10.</li><li>The company reported revenue of $232,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vcnx-stock-earnings-vaccinex-for-q2-of-2024/">VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024

An announcement from Vaccinex ( ($VCNX) ) is now available. Chrystyna Bedrij Stecyk has abruptly resigned as a director of Vaccinex, Inc., effectiv...

Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns

Vaccinex exercises warrants for proceeds of $6.2M

Vaccinex files for secondary stock offering

Vaccinex (VCNX) announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study ...

Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study

Vaccinex (VCNX) provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Vacci...

Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab

Reports Q3 revenue $52,000 vs. $20,000 last year. Cash and cash equivalents and marketable securities on September 30, 2024, were $2.9 million, as ...

Vaccinex reports Q3 EPS ($2.83) vs. ($15.25) last year

Vaccinex reports Q3 figures

VCNX

Press Releases

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease at the Alzheimer's Association International Conference, Philadelphia, July 31, 2024

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Financing

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Comments

Vaccinex

Vaccinex (VCNX) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌